HK124397A - Terazosin polymorph and pharmaceutical composition - Google Patents

Terazosin polymorph and pharmaceutical composition

Info

Publication number
HK124397A
HK124397A HK124397A HK124397A HK124397A HK 124397 A HK124397 A HK 124397A HK 124397 A HK124397 A HK 124397A HK 124397 A HK124397 A HK 124397A HK 124397 A HK124397 A HK 124397A
Authority
HK
Hong Kong
Prior art keywords
terazosin
polymorph
pharmaceutical composition
pharmaceutical
composition
Prior art date
Application number
HK124397A
Other languages
English (en)
Inventor
Glenn A Meyer
John F Bauer
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26733641&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK124397(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of HK124397A publication Critical patent/HK124397A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
HK124397A 1993-04-29 1997-06-26 Terazosin polymorph and pharmaceutical composition HK124397A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5491793A 1993-04-29 1993-04-29
US08/090,721 US5294615A (en) 1993-04-29 1993-07-13 Terazosin polymorph and pharmaceutical composition

Publications (1)

Publication Number Publication Date
HK124397A true HK124397A (en) 1997-09-12

Family

ID=26733641

Family Applications (1)

Application Number Title Priority Date Filing Date
HK124397A HK124397A (en) 1993-04-29 1997-06-26 Terazosin polymorph and pharmaceutical composition

Country Status (9)

Country Link
US (2) US5294615A (xx)
EP (1) EP0623612B1 (xx)
JP (1) JP2755895B2 (xx)
DE (1) DE69300913T2 (xx)
DK (1) DK0623612T3 (xx)
ES (1) ES2089665T3 (xx)
GR (1) GR3018433T3 (xx)
HK (1) HK124397A (xx)
MX (1) MX9306196A (xx)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5596109A (en) * 1992-03-24 1997-01-21 Smithkline Beecham Corporation N-t-butyl-androst-3,5-diene-17β-carboxamide-3-carboxylic acid polymorph A
US5412095A (en) * 1993-04-29 1995-05-02 Abbott Laboratories Terazosin monohydrochloride and processes and intermediate for its production
JPH07206857A (ja) * 1993-12-28 1995-08-08 Synthelabo Sa アルフゾシン塩酸塩の二水和物
US5504207A (en) * 1994-10-18 1996-04-02 Abbott Laboratories Process and intermediate for the preparation of terazosin hydrochloride dihydrate
US5587377A (en) * 1995-10-24 1996-12-24 Invamed, Inc. Terazosin crystalline polymorph and pharmaceutical compositions thereof
DE19546573A1 (de) * 1995-12-13 1997-06-19 Uetikon Chemie Gmbh Kristallines Polymorph von Terazosin-Hydrochlorid, sowie Verfahren zu seiner Herstellung
US5952003A (en) * 1996-08-01 1999-09-14 Novartis Corporation Terazosin capsules
IT1286790B1 (it) * 1996-11-29 1998-07-17 Alfa Chem Ital Processo per la produzione della forma i del terazosin monocloridrato anidro
IT1286789B1 (it) * 1996-11-29 1998-07-17 Alfa Chem Ital Processo per la produzione della forma i del terazosin monocloridato anidro
EP0849264A1 (de) * 1996-12-20 1998-06-24 HEUMANN PHARMA GmbH Neue polymorphe Form von doxazosinmesylat (Form I)
DK0849266T3 (da) * 1996-12-20 2007-06-04 Heumann Pcs Gmbh Hidtil ukendt polymorf form af doxazosin-mesylat (form III)
EP0849265A1 (de) * 1996-12-20 1998-06-24 HEUMANN PHARMA GmbH Neue polymorphe Form von Doxazosin-Mesylat (Form II)
US6248888B1 (en) 1997-11-14 2001-06-19 Teva Pharmaceutical Industries Ltd. Process for the preparation of terazosin hydrochloride dihydrate
AU4491200A (en) * 1999-08-03 2001-02-19 Lilly Icos Llc Beta-carboline pharmaceutical compositions
US6200573B1 (en) 1999-12-03 2001-03-13 Starcor Pharmaceuticals, Inc. Method of medical management for lower urinary tract symptoms and benign prostatic hyperplasia
DE10000792A1 (de) * 2000-01-11 2001-07-19 Bernhard C Lippold Formulierungen von Wirkstoffen in Form einer festen Dispersion
ATE405577T1 (de) * 2000-11-17 2008-09-15 Lilly Co Eli Lactam dipeptid und dessen verwendung zur inhibierung der beta-amyloid peptid frisetzung
US20030138483A1 (en) * 2001-05-25 2003-07-24 Sergio Petriconi Soft elastic capsules and compositions thereof
US8496960B2 (en) * 2001-10-23 2013-07-30 Purdue Pharma L.P. Terazosin transdermal device and methods
EP2316468A1 (en) 2002-02-22 2011-05-04 Shire LLC Delivery system and methods for protecting and administering dextroamphetamine
TWI353979B (en) * 2002-04-10 2011-12-11 Nippon Zoki Pharmaceutical Co Novel crystal form of 5-hydroxy-1-methylhydantoin
US7097967B2 (en) * 2002-10-24 2006-08-29 Lg Life Sciences Ltd. Method of predicting drug-food interaction
KR20040076203A (ko) * 2003-02-24 2004-08-31 주식회사 엘지생명과학 음식물-약물 상호작용을 방지하기 위한 경구 투여용약제학적 조성물 및 방법
CN101547696A (zh) * 2006-08-08 2009-09-30 奥斯拜客斯制药有限公司 具有α肾上腺素能阻断效应的取代喹唑啉化合物的制备和应用
CN102321563B (zh) 2011-10-24 2013-04-03 江南大学 一株拟无枝酸菌及利用其全细胞转化制备香草醛的方法
US9096428B2 (en) * 2013-03-08 2015-08-04 Taiwan Semiconductor Manufacturing Company, Ltd. Methods and apparatus for MEMS structure release
US11224572B1 (en) 2020-08-17 2022-01-18 Novitium Pharma LLC Stable oral liquid composition of terazosin

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4026894A (en) * 1975-10-14 1977-05-31 Abbott Laboratories Antihypertensive agents
GB1591490A (en) * 1977-08-04 1981-06-24 Abbott Lab 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-tetrahydrofuroyl)piperazine hydrochloride dihydrate
US5122514A (en) * 1990-04-23 1992-06-16 Abbott Laboratories Psoriasis treatment
US5212176A (en) * 1990-06-29 1993-05-18 Abbott Laboratories R(+)-terazosin
JP2652272B2 (ja) * 1990-12-31 1997-09-10 住化ファインケム株式会社 １−（４−アミノ−６，７−ジメトキシ−２−キナゾリニル）−４−（２−テトラヒドロフロイル）ピペラジン塩酸塩の新規な結晶体および該結晶体の製造方法

Also Published As

Publication number Publication date
DE69300913D1 (de) 1996-01-11
DE69300913T2 (de) 1996-05-02
DK0623612T3 (da) 1996-02-05
EP0623612B1 (en) 1995-11-29
GR3018433T3 (en) 1996-03-31
JP2755895B2 (ja) 1998-05-25
EP0623612A1 (en) 1994-11-09
MX9306196A (es) 1994-01-31
ES2089665T3 (es) 1996-10-01
JPH06312984A (ja) 1994-11-08
US5294615A (en) 1994-03-15
US5362730A (en) 1994-11-08

Similar Documents

Publication Publication Date Title
HK124397A (en) Terazosin polymorph and pharmaceutical composition
HU9402974D0 (en) Pharmaceutical composition
ZA947305B (en) Pharmaceutical compositions and usages
IL119078A (en) Substituted benzylaminopiperidine compounds and pharmaceutical compositions comprising them
GB9317686D0 (en) Pharmaceutical compositions
IL110201A0 (en) Novel pharmaceutical compositions
GB9317610D0 (en) Pharmaceutical compositions
GB9316580D0 (en) Pharmaceutical composition
GB2272375B (en) Pharmaceutical composition
PL314036A1 (en) Pharmaceutical composition
CA2100836A1 (en) Pharmaceutical composition
GB9317504D0 (en) Pharmaceutical compositions
ZA945752B (en) Pharmaceutical composition
GB9318880D0 (en) Pharmaceutical composition
HU9401771D0 (en) Pharmaceutical compositions cintaining ipsapiron
GB9420129D0 (en) Pharmaceutical compositions
GB9321671D0 (en) Pharmaceutical composition
GB9308849D0 (en) Pharmaceutical composition
GB9314564D0 (en) Pharmaceutical composition
GB9417021D0 (en) Pharmaceutical composition
GB9314709D0 (en) Pharmaceutical composition
ZA935269B (en) Pharmaceutical composition
GB9320688D0 (en) Pharmaceutical composition
HU9303386D0 (en) Pharmaceutical composition
HU9303511D0 (en) Pharmaceutical composition

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)